Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
Status:
Not yet recruiting
Trial end date:
2027-01-20
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of irinotecan liposomes with oxaliplatin, 5-fluorouracil
(5-FU) / leucovorin (LV) with or without adelizumab for resectable pancreatic cancer by
assessing the 12-month EFS rate